...
机译:第一代EGFR-TKIS反对非小细胞肺癌的结果,涉及罕见的EGFR突变:对BE阳性研究的后HOC分析
Medical Oncology University of Verona Azienda Ospedaliera Universitaria Integrata di Verona;
Division of Medical Oncology S.G. Moscati Hospital;
Department of Oncology University of Torino AOU San Luigi;
Department of Oncology University Hospital of Udine;
Medical Oncology Unit University Hospital of Parma;
Medical Oncology Unit Clinical Cancer Center Giovanni Paolo II;
Thoracic Medical Oncology National Cancer Institute Fondazione “G. Pascale”;
Medical Oncology Mauriziano Hospital Department of Oncology University of Turin;
Medical Oncology S. Giovanni-Addolorata Hospital;
Medical Oncology Unit Santa Chiara Hospital;
Medical Oncology Unit AO SS. Antonio Biagio e Cesare Arrigo;
Medical Oncology Unit AOU San Gerardo;
Department of Medical Oncology Fondazione IRCCS Istituto Nazionale dei Tumori;
Medical Oncology Unit Valduce Hospital;
Division of Medical Oncology AO Cannizzaro Hospital;
Medical Oncology Unit A. Manzoni Hospital;
Division of Medical Oncology S.G. Moscati Hospital;
Department of Medical Oncology National Institute for Cancer Research;
Department of Medical Oncology IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei;
Department of Oncological Medicine Ramazzini Hospital;
UOC Medical Oncology AO Luigi Sacco;
Department of Oncology University Hospital of Udine;
EORTC Headquarters;
Department of Oncology and Hemathology AOU of Modena;
Lung Cancer Unit IRCCS AOU San Martino-IST Istituto Nazionale per la Ricerca sul Cancro;
Medical Oncology Unit University Hospital Careggi;
Division of Thoracic Oncology European Institute of Oncology;
Medical Oncology University of Verona Azienda Ospedaliera Universitaria Integrata di Verona;
Department of Oncology University of Torino AOU San Luigi;
Erlotinib; Gefitinib; G719X; Heterogeneity outcome; L861Q;
机译:第一代EGFR-TKIS反对非小细胞肺癌的结果,涉及罕见的EGFR突变:对BE阳性研究的后HOC分析
机译:第一代EGFR-TKI在具有EGFR外显子20突变的晚期非小细胞肺癌患者中的临床疗效
机译:EGFR-TKI立交合物的II期试验与AFATINIB在先进的非小细胞肺癌中,含有敏感的非T790M EGFR突变:冈山肺癌研究组试验1403
机译:下一代测序对非小细胞肺癌抗蛋白酶激酶抑制剂进行下一代测序检测的低负荷EGFR突变的预测疗效
机译:EGFR-TKIs在非小细胞肺癌治疗中的有效性:一项荟萃分析。
机译:第一代EGFR-TKI在具有EGFR外显子20突变的晚期非小细胞肺癌患者中的临床疗效
机译:第一代EGFR-TKI的疗效和安全性联合化疗治疗治疗 - 幼稚高级非小细胞肺癌患者,涉及敏感EGFR突变:单中心,开放标签,单臂,II期临床试验